Page 9 - Patrick Wingrove News Today

(Reuters) -Moderna on Thursday said it expected 2023 revenue of at least $6 billion, tempering its forecast to reflect weaker demand for COVID-19 vaccines, but added it would return to sales growth in 2025 and break even the following year. The company reported third-quarter sales of $1.8 billion, topping analysts' estimates of $1.32 billion, according to LSEG data. Moderna's COVID-19 vaccine is its lone marketed product.

By Maggie Fick and Bhanvi Satija (Reuters) - Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to exten...

Belgium’s drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisks popular obesity drug Wegovy, in which the injector pens contained insulin.

Belgium’s drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisks popular obesity drug Wegovy, in which the injector pens contained insulin. ...

Belgium’s drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisk's popular obesity drug Wegovy, in which the injector pens contained insulin. The Federal Agency for Medicines and Health Products told Reuters that this year it had detained nine mailed packages of GLP-1 medicines, the class of drugs that includes Wegovy and Novo's diabetes drug Ozempic, on the suspicion that they were fake.

By Patrick Wingrove (Reuters) - Belgium's drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisk...

Eli Lilly on Thursday said it sued 11 online pharmacies to stop them from importing, selling and distributing products claiming to contain the active ingredient in its diabetes drug Mounjaro, which is expected to be approved for weight loss later this year. The Indianapolis-based drugmaker said the suit will go to the U.S. International Trade Commission (ITC). It names the U.S.-based Artic Peptides, Strate Labs, Supopeptide, The Triggered Brand, and Unewlife as defendants, along with Britain’s...

Extraordinary demand for Novo Nordisk’s Ozempic and other drugs used for weight-loss is fueling a global surge in counterfeit versions, according to Reuters interviews with law enforcement, anti-counterfeiting and public health officials. The U.S.-based Pharmaceutical Security Institute (PSI), an industry-backed organization that counts drugmakers Novo Nordisk and Eli Lilly as members, said it is working with agencies, including Europol, Interpol and U.S. Homeland Security, as well as co...

By Bhanvi Satija and Patrick Wingrove (Reuters) - Johnson & Johnson on Tuesday said it has embarked on a two-year restructuring program for its ...

The FDA on Tuesday published letters warning two online vendors to stop selling unapproved versions of semaglutide and tirzepatide.